Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
5 undervalued US stocks that crushed earnings
Names like Sony and GSK are still cheap despite impressive earnings beats for Q2 2024.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,365.70 | 24.70 | 0.30% |
| CAC 40 | 7,593.87 | 38.00 | 0.50% |
| DAX 40 | 22,496.98 | 71.15 | 0.32% |
| Dow JONES (US) | 40,669.36 | 141.74 | 0.35% |
| FTSE 100 | 8,496.58 | 1.73 | 0.02% |
| HKSE | 22,119.41 | 111.30 | 0.51% |
| NASDAQ | 17,446.34 | 14.98 | -0.09% |
| Nikkei 225 | 36,452.30 | 406.92 | 1.13% |
| NZX 50 Index | 12,148.60 | 245.29 | 2.06% |
| S&P 500 | 5,569.06 | 8.23 | 0.15% |
| S&P/ASX 200 | 8,145.60 | 19.40 | 0.24% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |